BHC Stock Summary and Trading Ideas (Bausch Health Companies | NYSE:BHC)

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Bausch Health Companies trades on the NYSE stock market under the symbol BHC.

As of March 14, 2025, BHC stock price climbed to $7.15 with 1,853,653 million shares trading.

BHC has a beta of 0.29, meaning it tends to be less sensitive to market movements. BHC has a correlation of 0.00 to the broad based SPY ETF.

BHC has a market cap of $2.63 billion. This is considered a Mid Cap stock.

Last quarter Bausch Health Companies reported $3 billion in Revenue and $1.17 earnings per share. This beat revenue expectation by $35 million and missed earnings estimates by -$.02.

In the last 3 years, BHC traded as high as $24.26 and as low as $3.96.

The top ETF exchange traded funds that BHC belongs to (by Net Assets): DFIS, PPH, DFIC, DFAX, GVLU.

BHC has underperformed the market in the last year with a price return of -23.0% while the SPY ETF gained +10.4%. BHC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.5% and -6.5%, respectively, while the SPY returned -6.5% and -3.8%, respectively.

BHC support price is $6.73 and resistance is $7.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHC shares will trade within this expected range on the day.